Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies

Bauer, Renato A.·2015·Drug Discovery Today
DOI 10.1016/j.drudis.2015.05.005

Cited by (579)

Items 401–500 of 579

  1. Development of “Furan Warhead”-Equipped Antagonistic Nanobodies for Covalent Cross-Linking to the Epidermal Growth Factor Receptor
    Laure Tack, Laia Miret‐Casals, Olivier Zwaenepoel, Enrico Cadoni, Marleen Van Troys, Jan Gettemans, Annemieke Madder · 2025 · Bioconjugate Chemistry
  2. Collective Total Synthesis of a Unique Class of Liverworts‐Derived Cembrane Diterpenoids
    A. Hermann, Alois Fürstner · 2025 · Angewandte Chemie International Edition
  3. Synthesis and characterization of bicyclo[1.1.0]butane amides and 5-methylene-3-azabicyclo[5.1.0]octan-4-ones as covalent modifiers
    Karis Texidor, Dilhumar Uyghur, Noah Wiese, Lindsey O. Davis, Mandy Green, Farjana Sharmen, Adil Ijaz, Kamani M. Barnes, Madison Bagett, Jishi Ye et al. · 2026 · Bioorganic & Medicinal Chemistry Letters
  4. Lysine-Targeted Covalent Inhibitors: Emerging Warheads and Expanding Applications in Medicinal Chemistry
    Yue Wu, Yuehua Chen, 曹瑞恆, Xiang Li, Xiaojin Zhang · 2026 · Journal of Medicinal Chemistry
  5. Rapid and cost-effective screening of therapeutic targets for isoquercitrin in insulin resistance using virtual methods and fiber SPR biosensing
    Yong Shuai Wei, Yuye Xuan, Wenxiang Wang, Yonghui Zhang, Xiaoshan Li, Chunlan Liu, Chen Wang, Zhihai Liu · 2025 · Biomedical Optics Express
  6. Development of Efficient Covalent Inactivators of a Fungal Aspartate Semialdehyde Dehydrogenase
    Samantha N. Friday, Liezel A. Koellner, Spencer W. Brown, Christopher N. Calbat, Catherine F. Curran, Jordan D. Dietz, Andreas Koenig‐Dummer, Paul D. Friday, James A. Parker, Noah A. Simmons et al. · 2025 · Drug Development Research
  7. 3, 3′-[succinylbis(diazaneyl)]bis(N,N,N-trimethylpropan-1-ammonium) perchlorate: Synthesis, characterization, computational studies and in vitro anticancer activity against the human colon carcinoma cell line (HT-29)
    Sahin Reja, Kaushik Sarkar, Deboshmita Mukherjee, T. K. S. Fayaz, Pranesh Kumar, Purak Das, Palash Sanphui, Rajesh Kumar Das · 2022 · Journal of Molecular Structure
  8. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease
    Ying Wang, Qiushuang Gao, Yao Peng, Qizheng Yao, Ji Zhang · 2023 · Journal of Biomolecular Structure and Dynamics
  9. Computational and biophysical methods for the discovery and optimization of covalent drugs
    Guanyu Wang, Nicolas Moitessier, Anthony Mittermaier · 2023 · Chemical Communications
  10. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC)
    Huimin Xue, Peng Chen, Jingyi Jiao, Xiaojun Zhu · 2024 · The Protein Journal
  11. Chemoproteomics‐Enabled De Novo Discovery of Photoswitchable Carboxylesterase Inhibitors for Optically Controlled Drug Metabolism
    Brendan G. Dwyer, Chao Wang, Daniel Abegg, Brittney Racioppo, Nan Qiu, Zhen‐Sheng Zhao, Dany Pechalrieu, Anton Shuster, Dominic G. Hoch, Alexander Adibekian · 2020 · Angewandte Chemie
  12. Gibbs Free Energy of Hydrolytic Water Molecule in Acyl-Enzyme Intermediates of a Serine Protease: A Potential Application for Computer-Aided Discovery of Mechanism-Based Reversible Covalent Inhibitors
    Yosuke Masuda, Noriyuki Yamaotsu, Shuichi Hirono · 2017 · Chemical and Pharmaceutical Bulletin
  13. Linear Discriminant Analysis for the in Silico Discovery of Mechanism-Based Reversible Covalent Inhibitors of a Serine Protease: Application of Hydration Thermodynamics Analysis and Semi-empirical Molecular Orbital Calculation
    Yosuke Masuda, Tomoki Yoshida, Noriyuki Yamaotsu, Shuichi Hirono · 2018 · Chemical and Pharmaceutical Bulletin
  14. Evaluation of the changes in exposure to thiol compounds in chronic kidney disease patients using the PBPK model
    Hiroaki Takubo, Toshio Taniguchi, Kazunori Iwanaga, Yukihiro Nomura · 2020 · Xenobiotica
  15. Pairs of thiol-substituted 1,2,4-triazole-based isomeric covalent inhibitors with tunable reactivity and selectivity
    Shiqi Xu, Zi Ye, Shuang Shang, Fengge Wang, Huan Zhang, Lianguo Chen, Hao Lin, Chen Chen, Fang Hua, Chong‐Jing Zhang · 2023 · Chinese Chemical Letters
  16. Inhibition of SARS-CoV-2 Main Protease: A Repurposing Study That Targets the Dimer Interface of the Protein
    Hanife Pekel, Metehan Ilter, Özge Şensoy · 2020 · ChemRxiv
  17. Kinase Inhibitors
    Peng Wu, Michael Givskov, Thomas E. Nielsen · 2017 · Methods and principles in medicinal chemistry
  18. High-efficiency discovery and structure-activity-relationship analysis of non-substrate-based covalent inhibitors of S-adenosylmethionine decarboxylase
    Yuanbao Ai, Siyu Xu, Yan Zhang, Zhaoxiang Liu, Sen Liu · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  19. Quinate-based ligands for irreversible inactivation of the bacterial virulence factor DHQ1 enzyme—A molecular insight†
    Ángela Rodríguez, Marı́a Maneiro, Emilio Lence, José M. Otero, Mark J. van Raaij, Paul Thompson, Alastair R. Hawkins, Concepción González‐Bello · 2023 · Frontiers in Molecular Biosciences
  20. Structural insight into the unexploited allosteric binding site of fructose 1, 6-bisphosphate aldolase from C. albicans with α-lipoic acid
    Hongxuan Cao, Zeyue Huang, Xiaohong Hu, Xiao Zhang, Nokwanda Pearl Makunga, Huijun Zhao, Liji Du, Li Guo, Yanliang Ren · 2025 · International Journal of Biological Macromolecules
  21. Programmable synthesis of alkaloidal frameworks integrating Michael acceptor generates covalent probes for targeting POLE3 in HBV replication
    Nobuto Kaneko, Misao Himeno, Yuhi Kobayashi, Ryo Tanifuji, Hiroki Kubota, Haruki Mizoguchi, Makoto Muroi, Takehiro Suzuki, Masaya Sugiyama, Naoshi Dohmae et al. · 2025 · RSC Chemical Biology
  22. Structural diversity of aldehydes determines covalent versus non-covalent inhibition mechanisms against steroid 5α-reductase type 1: Species-specific differences and preliminary structure-activity relationships
    Junying Chen, Shufang Qi, Zijian Lin, Haonan Fang, Putian Zhang, Wanyu Li, Ren-shan Ge, Yiyan Wang · 2025 · Chemico-Biological Interactions
  23. Ultrasound-guided and activated nanodrugs for highly selective tumor therapy
    Chuwen Luo, Ya Liu, Weidong Zhao, Jingchen Du, 谈文叶, Yajun Xu, Zhaohui Tang, Xuesi Chen · 2026 · Journal of Controlled Release
  24. Systematic Evaluation of Electrophile Reactivity and Stability for Covalent DNA‐Encoded Libraries
    Johanna Puff, Giulia Assoni, Jiannan Zhao, Qi Zhang, Zhongyao Ma, Huan Liu, Weiren Cui, Alexander Lee Satz, Wenji Su, Letian Kuai et al. · 2026 · Helvetica Chimica Acta
  25. Covalent Targeting of Histidine Residues: A Ligand-First Approach
    Giulia Alboreggia, Emma L. Atienza, Kendall Marie Muzzarelli, Zahra Assar, Maurizio Pellecchia · 2026 · Journal of Medicinal Chemistry
  26. The Search for Covalently Ligandable Proteins in Biological Systems
    Syed Lal Badshah, Yahia N. Mabkhot · 2016 · Molecules
  27. Covalent drugs in development for immune-mediated diseases
    Leonard Sung · 2021 · Annual reports in medicinal chemistry
  28. Thermal Stability and Utility of Dienes as Protecting Groups for Acrylamides
    Annie R. Hooper, Alexander S. Burns · 2022 · ACS Medicinal Chemistry Letters
  29. Covalent Modifier Discovery Using Hydrogen/Deuterium Exchange–Mass Spectrometry
    Hiroyuki Kojima, Ryota Yanagi, Eri Higuchi, Mami Yoshizawa, Tomoyuki Shimodaira, Misaki Kumagai, Tatsuhiro Kyoya, Miyu Sekine, Daichi Egawa, Nami Ohashi et al. · 2023 · Journal of Medicinal Chemistry
  30. Drug development of covalent inhibitors
    Upendra P. Dahal, Jan L. Wahlstrom · 2023 · Elsevier eBooks
  31. Covalency-enabled Drug Discovery is Redefining Druggability
    Jeffrey M. McKenna, Rupert S. J. Proctor · 2023 · CHIMIA International Journal for Chemistry
  32. A General Protocol for the Chemo- and Stereoselective Construction of α,β-Unsaturated γ-Amino Sulfonyl Fluorides
    Hua‐Li Qin, Xiang-Feng Tao · 2023 · Synthesis
  33. Computational Investigations on Reaction Mechanisms of the Covalent Inhibitors Ponatinib and Analogs Targeting the Extracellular Signal-Regulated Kinases
    Yafeng Tian, Mi Zhang, Panpan Heng, Hua Hou, Baoshan Wang · 2023 · International Journal of Molecular Sciences
  34. Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation
    Mohammad Hossein Haghir Ebrahim Abadi, Fatemeh Bayani, Yahya Sefidbakht · 2025 · Scientific Reports
  35. Covalent inhibitors in Parkinson's disease: Molecular targeting strategies for neuroprotective intervention
    Devadharuna Mohan, Raghul Venkatesan, Amarjith Thiyyar Kandy, Santhoshkumar Muthu, J. Saravanan, Rajinikanth Baskaran, Palanisamy Pethappachetty, Divakar Selvaraj · 2025 · Molecular and Cellular Neuroscience
  36. The art of suicidal molecular seduction for targeting drug resistance
    Mohammad Hassan Moshafi, Saeid Ghasemshirazi, Ardavan Abiri · 2020 · Medical Hypotheses
  37. Novel active pharmaceutical ingredients from India
    PrasantaKumar Ghosh · 2021 · MGM Journal of Medical Sciences
  38. Reactivity-based chemical-genetic study of protein kinases
    Renata Rezende Miranda, Chao Zhang · 2022 · RSC Medicinal Chemistry
  39. A primer on harnessing non-enzymatic post-translational modifications for drug design
    Marcus J. C. Long, Phillippe Ly, Yimon Aye · 2021 · RSC Medicinal Chemistry
  40. New Chemical Biology Tools for the Histamine Receptor Family
    Yang Zheng, Gábor Wágner, Niels J. Hauwert, Xiaoyuan Ma, Henry F. Vischer, Rob Leurs · 2022 · Current topics in behavioral neurosciences
  41. Calculating the Full Free Energy Profile for Covalent Modification of a Druggable Cysteine in Bruton’s Tyrosine Kinase
    Ernest Awoonor‐Williams, Christopher N. Rowley · 2020 · ChemRxiv
  42. QM / MM for Structure‐Based Drug Design: Techniques and Applications
    Marc W. van der Kamp, Jaida Begum · 2024 · Wiley eBooks
  43. Genotoxicity
    Stephan Kirchner, Patrick Schnider · 2021 · Royal Society of Chemistry eBooks
  44. Thiol modification and signaling by biological electrophiles
    Francisco Jose Schopfer, Darío A. Vitturi · 2022 · Elsevier eBooks
  45. Non-equilibrium modalities of inhibition: Characterizing irreversible inhibition for the ErbB receptor family members
    Bharath Srinivasan · 2023 · Methods in enzymology on CD-ROM/Methods in enzymology
  46. Enzymatic Targets for Drug Discovery Against Alzheimer's Disease
    Ahmet Ozan ÖZGEN, Ozan Emre Eyüpoğlu · 2023 · BENTHAM SCIENCE PUBLISHERS eBooks
  47. Chemical Proteomics Approaches for Screening Small Molecule Inhibitors Covalently Binding to SARS‐Cov‐2
    Liu-hai Zheng, Qian Zhang, Piao Luo, Fei Shi, Ying Zhang, Xiao-Xue He, Ye-Hai An, Guangqing Cheng, Xiaoya Pan, Zhijie Li et al. · 2024 · Advances in Biology
  48. Design and Synthesis of Novel MEK Inhibitors for the Treatment of Solid Tumors
    Jing Zeng, Zhenshuo Luo, Tiansheng Zhao, Chunhua Xia, Fanglan Liu, Na Li, Lailiang Qu, Cheng Wang · 2025 · Chemical Biology & Drug Design
  49. Chemical Proteomics Unraveling the Contribution of Covalent Protein Modifications to Antidepressant Effects of Ketamine
    Xiaolan Hu, Jiwei Liu, Jian‐Lin Wu, Zhi‐Qi Xiong, Na Li · 2025 · Journal of Analysis and Testing
  50. Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
    Sara Amberntsson, Alison J. Foster, Bhavik Chouhan, Stephen D. Wilkinson, Stephanie Harlfinger, Graham Smith, Jason G. Kettle, Michael J. Niedbala, Stefan L. Kavanagh, Dominic P. Williams · 2025 · Toxicology Research
  51. Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 MPro protein - an in silico and cell-based approach
    Khushboo Singh, J. J. Patten, Andrea Dimet‐Wiley, Robert A. Davey, Stanley J. Watowich, Amit Chandra, Jesse C. Leverett · 2025 · Scientific Reports
  52. Palladium-catalyzed in vivo bioorthogonal activation of N , N -dialkyl-α-hydroxymethyl acrylamide for efficient payload release
    Ruipeng Shen, Baoxin Zhang, Jirong Liu, Meirong Yi, Yating Chen, Jianguo Fang · 2025 · Journal of Materials Chemistry B
  53. Structure-guided discovery of a small molecule inhibitor of SARS-CoV-2 main protease with potent in vitro and in vivo antiviral activities
    Shuofeng Yuan, Juan Wang, Xiaohong Sang, Yubin Xie, Yong Feng, Vincent Kwok‐Man Poon, Chris Chung‐Sing Chan, Jessica Oi‐Ling Tsang, Kenn Ka‐Heng Chik, Jiao Zhou et al. · 2025 · Journal of Virology
  54. Computationally guided design of N4-(2-methyl-2H-indazol-6-yl)-N2-phenylpyrimidine-2,4-diamine inhibitors of EGFR kinase targeting Cys797
    Adchata Konsue, Duangkamol Gleeson, Kiattawee Choowongkomon, Donald J. L. Jones, Pimkhuan Hannanta‐anan, Robert G. Britton, M. Paul Gleeson · 2026 · Bioorganic & Medicinal Chemistry
  55. Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening
    Yangping Deng, S P Li, Liang Wang, Jianping Lin, Haohao Fu, Jing Li, Yue Chen · 2026 · Journal of Chemical Information and Modeling
  56. Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition
    Matthew L. Condakes, Rita L. Civiello, Brian L. Venables, Derek B. Danahy, Richard R. Moore, Srividya B. Balachander, Lisa Sinang Chourb, Daniel P. Downes, Dieter M. Drexler, Liudmila Dzhekieva et al. · 2026 · Journal of Medicinal Chemistry
  57. Covalent drugs reimagined: from cysteine-targeted inhibitors to proteome-informed precision therapeutics
    Ahmed Ali Al-Karmalawy, Wolfgang Sippl, Abdullah Al-Dakhil, Tarek A. Yousef, Arwa Omar Al Khatib, Samia S. Hawas · 2026 · Bioorganic Chemistry
  58. A multicomponent reaction-enabled discovery platform reveals a TXNRD1-targeted ferroptosis inducer
    Xiang Fu, Qiong Wu, Siyu Wu, Gejun Niu, Zhonghui Zhang, Yue Lin, Yu Cao, Yaxin Li, Feng Xiong, Yu Qian et al. · 2026 · The Innovation Drug Discovery
  59. A Perspective on Covalent Hit Identification and Validation in the European Pharmaceutical Industry
    Oliver Schadt, Sebastian Essig, Giambattista Testolin · 2026 · ChemBioChem
  60. Coping with Complexity in Ligand-Based De Novo Design
    Gisbert Schneider, Petra Schneider · 2016 · ACS symposium series
  61. Drug discovery
    Susan M. Miller, Walter H. Moos, Barbara H. Munk, Stephen A. Munk · 2016 · Elsevier eBooks
  62. Molecular Dynamics, Quantum Mechanics, and Combined Quantum Mechanics/Molecular Mechanics Methods for Drug Discovery and Development
    Eric J. M. Lang, Adrian John Mulholland · 2017 · Elsevier eBooks
  63. Deciphering the chemical instability of sphaeropsidin A under physiological conditions – degradation studies and structural elucidation of the major metabolite
    Alet E. van der Westhuyzen, Aude Ingels, Rémi Rosière, Karim Amighi, Lukas Oberer, Kirk R. Gustafson, Dongdong Wang, Antonio Evidente, Lucia Maddau, Marco Masi et al. · 2020 · Organic & Biomolecular Chemistry
  64. Computational support of structure-based targeted covalent inhibitor design
    Robert Abel, Richard A. Friesner · 2021 · Annual reports in medicinal chemistry
  65. A Screening System for the Identification of Fragment Molecules toward the Creation of Nuclear Receptor Ligands
    Yusaku Miyamae · 2022 · YAKUGAKU ZASSHI
  66. Structure-based methods in drug design
    Lalitha Guruprasad, Priyanka Andola, Adrija Banerjee, Laxman Durgam, Gatta K. R. S. Naresh · 2023 · Elsevier eBooks
  67. Computational Modeling in the Development of Antiviral Agents
    Priyank Purohit, Pobitra Borah, Sangeeta Hazarika, Gaurav Joshi, Pran Kishore Deb · 2023 · Challenges and advances in computational chemistry and physics
  68. Enzymology in drug discovery
    Sailee Chowdhury, Koyel Kar, Priyanka Chakraborty · 2024 · Elsevier eBooks
  69. The Synthesis of (2R)-Aziridine-2-carboxylic Acid Containing Dipeptides
    Samo Kuzmič, Martina Hrast, Rok Frlan · 2022 · Acta chimica slovenica
  70. Prospects of Covalent Approaches in Drug Discovery: An Overview
    Balajee Ramachandran, Muthupandian Saravanan, Jeyaraman Jeyakanthan · 2021 · Wiley eBooks
  71. Dimethyl fumarate as a covalent inhibitor of Cathepsin C: a novel mechanism of action explored in in-vitro and in-vivo.
    Qadir Alam, Sairam Krishnamurthy, Munendra Tomar · 2023 · Research Square
  72. Design strategies for new drugs targeting multicomponent systems : focusing on class II MHC proteins and acetylcholinesterase
    Cecilia M. Lindgren · 2017 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  73. Design, synthesis and biophysical evaluation of peptides targeting pharmacologically relevant proteins
    Salvador Guardiola Bagán · 2017 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  74. Ensaio enzimático on-line baseado em enzimas imobilizadas e cromatografia zonal para identificação e caracterização de inibidores da enzima Nucleosídeo Difosfato Quinase B
    Juliana Maria de Lima · 2018 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  75. An Investigation into the Adduct Forming Potential of Drugs of Abuse with Peptides and Proteins
    Richard Allen Gilliland · 2018
  76. Pharmacological Targeting of Sphingosine Kinase: Conventional, Bisubstrate, and Irreversible Inhibitors
    Thomas K. Dawson · 2016
  77. Baccalaureate and Higher Degree Program's Accreditation Committee reports on evaluation data.
    C M Schultz, Linda Niedringhaus · 1995 · PubMed
  78. Anti-Virulence Strategy Targeting Sortase A, A Structural Investigation of the Sortase A Enzyme, and the Identification, Synthesis, and Evaluation of Sortase A Inhibitors
    Ivana Uzelac · 2019 · Gothenburg University Publications Electronic Archive (Gothenburg University)
  79. Covalent inhibition of cyclin dependent kinase 2 (CDK2) through modification of a non-catalytic lysine side chain
    Nathalie Myrthil · 2019
  80. Modulating the Reactivity of Electrophilic Warheads for Pharmacokinetic Efficacy
    Mariya Bogatchenko · 2018 · TSpace (University of Toronto)
  81. Enzymes as Drug Targets
    Thomas D. Meek · 2021 · Wiley eBooks
  82. Squaric ester applications as novel lysine electrophiles in molecular probe design
    Jordan Sun Ho · 2020 · DSpace@MIT (Massachusetts Institute of Technology)
  83. Allosteric regulation of BTK by the PHTH domain and small molecules
    Neha Amatya · 2021 · Iowa State University Digital Repository (Iowa State University)
  84. Exploration of BAY 11-7082 as a novel antibiotic
    Victoria E. Coles, Patrick Darveau, Xiong Zhang, Hanjeong Harvey, Brandyn D. Henriksbo, Angela Yang, Jonathan D. Schertzer, Jakob Magolan, Lori L. Burrows · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Insight into the Binding Energetics of Targeted Reversible Covalent Inhibitors of the SARS-CoV-2 Main Protease
    Ernest Awoonor‐Williams · 2021 · ChemRxiv
  86. Inhibition studies on the human 20S proteasome: molecular insights from a computational approach
    Natalia Serrano-Aparicio · 2022
  87. Stabilized Peptide Covalent Inhibitors
    Zigang Li, Hui Zhao, Chuan Wan · 2021 · Wiley eBooks
  88. Drug discovery: Standing on the shoulders of giants
    Susan M. Miller, Walter H. Moos, Barbara H. Munk, Stephen A. Munk, Charles P. Hart, David C. Spellmeyer · 2023 · Elsevier eBooks
  89. Pairs of Triazole-Based Isomeric Covalent Inhibitors with Tunable Reactivity and Selectivity
    Chong‐Jing Zhang, Shiqi Xu, Zi Ye, Shuang Shang, Fengge Wang, Huan Zhang, Lian-guo Chen, Hao Lin, Chen Chen, Fang Hua · 2023 · SSRN Electronic Journal
  90. Sulfonyl fluorides as warheads in drug discovery
    Ruiqi Liu, Junbiao Chang · 2023 · Elsevier eBooks
  91. Strain-selective in vitro and in silico structure activity relationship (SAR) of N-acyl β-lactam broad spectrum antibiotics
    Ayeeshi Poosarla, Ria Kolala, Pranjal Verma, Anvi Surapaneni, Atri Surapaneni, Udbhav Avadhani, Chandraki Chatterjee, Sarah Wang-Zhou, Stacey Le, Emily Goyal et al. · 2021 · Journal of Emerging Investigators
  92. REVIEW OF SERINE PROTEASE INHIBITORS: DEVELOPMENT AND APPLICATIONS
    Mai Ramadan · 2023 · Bulletin of Pharmaceutical Sciences Assiut
  93. Molecular recognition of anion binding proteins: Characterization and inhibition
    Zachariah P. Schuurs · 2023 · Queensland University of Technology
  94. Comparative study of covalent & non-covalent drug inhibitory mechanism investigation: targeting HSP72 protein in cancer therapy using molecular modelling techniques.
    Aimen Aljoundi · 2021
  95. Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX
    Aivaras Vaškevičius, Denis Baronas, Jānis Leitāns, Agnė Kvietkauskaitė, Audronė Rukšėnaitė, E. Manakova, Zigmantas Toleikis, Algirdas Kaupinis, Andris Kazāks, Marius Gedgaudas et al. · 2024 · eLife
  96. Covalency in PROTACs: Mechanisms and applications
    Thomas M. Geiger, Radosław P. Nowak · 2024 · Annual reports in medicinal chemistry
  97. Covalent Inhibitors of MAP Kinases
    Surya Kanta De · 2024 · Springer eBooks
  98. Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX
    Aivaras Vaškevičius, Denis Baronas, Jānis Leitāns, Agnė Kvietkauskaitė, Audronė Rukšėnaitė, E. Manakova, Zigmantas Toleikis, Algirdas Kaupinis, Andris Kazāks, Marius Gedgaudas et al. · 2024 · eLife
  99. Covalent drugs
    Marta Kučerová-Chlupáčová · 2025 · Česká a slovenská farmacie
  100. High-Efficiency Discovery and Structure–Activity-Relationship Analysis of Nonsubstrate-Based Covalent Inhibitors of S -Adenosylmethionine Decarboxylase
    Yuanbao Ai, Siyu Xu, Yan Zhang, Zhaoxiang Liu, Sen Liu · 2025 · Journal of Medicinal Chemistry